Related Experiment Video

Updated: Nov 22, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.1K

Elbasvir and grazoprevir for the treatment of hepatitis C

Szu-Jen Wang1,2, Chung-Feng Huang3,4, Ming-Lung Yu1,3,4

  • 1Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Expert Review of Anti-Infective Therapy
|January 11, 2021
PubMed

Insights

Elbasvir/Grazoprevir (EBR/GZR) offers a highly effective treatment for Hepatitis C Virus genotypes 1 and 4 infections. This direct-acting antiviral combination demonstrates excellent efficacy and a high barrier to resistance, improving patient outcomes.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic Hepatitis C (HCV) remains a significant global health concern.
  • Direct-acting antivirals (DAAs) have transformed HCV treatment, achieving high sustained virological response rates (>95%).

Purpose of the Study:

  • To review the pharmacokinetics, pharmacodynamics, efficacy, and safety of Elbasvir/Grazoprevir (EBR/GZR).
  • To evaluate EBR/GZR as a treatment option for specific HCV genotypes.

Main Methods:

  • Review of clinical trials and real-world data on Elbasvir/Grazoprevir.
  • Analysis of pharmacokinetic and pharmacodynamic profiles.
  • Assessment of safety and tolerability data.

Main Results:

  • Elbasvir/Grazoprevir (EBR/GZR) is a combination therapy targeting NS5A and NS3/4A viral proteins.
  • EBR/GZR demonstrates high efficacy in treating HCV genotypes 1 and 4 infections.
  • The combination exhibits favorable safety and tolerability profiles in clinical practice.

Conclusions:

  • Elbasvir/Grazoprevir (EBR/GZR) is an effective treatment for HCV GT1 and GT4.
  • The drug combination possesses a high barrier to resistance-associated substitutions.
  • EBR/GZR represents a valuable therapeutic option in the management of chronic hepatitis C.

Keywords:
Direct-acting antiviralsdrug-drug interactionefficacyelbasvirgenotype 1 or 4grazoprevirhepatitis C virussafetysustained viral responsetolerability

More Related Videos

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.4K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.1K

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.6K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
311
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
756
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
312
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
13.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
287